[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465006":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":73,"collaborators":12,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":12,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":12,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":12,"overallStatus":96,"whyStopped":12,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Woolcock Institute of Medical Research","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"CPAP off condition","NO_INTERVENTION","Participants will be monitored for a two-week period prior to commencing CPAP.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"CPAP on condition","EXPERIMENTAL","Participants will be monitored for a two-week period at least four weeks following commencement of CPAP.",[18],"Device: CPAP",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","CPAP","A positive CPAP intervention",[14],[26],{"name":27,"affiliation":5,"role":28},"Craig L Phillips, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"David J Sherring, MBBS, DClinD","CONTACT","0407886698","dshe7670@uni.sydney.edu.au",[36,56],{"facility":37,"status":12,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Royal Prince Alfred Hospital","Camperdown","New South Wales","2050","Australia","AU",{"type":44,"coordinates":45},"Point",[46,47],151.17642,-33.88965,{"lat":47,"lon":46},[50,54],{"name":51,"role":32,"phone":52,"phoneExt":12,"email":53},"Estelle Ali","+61 468805641","estelle.ali@health.nsw.gov.au",{"name":55,"role":28,"phone":12,"phoneExt":12,"email":12},"Professor Brendon Yee",{"facility":5,"status":12,"city":57,"state":39,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Macquarie Park","2113",{"type":44,"coordinates":60},[61,62],151.12757,-33.78105,{"lat":62,"lon":61},[65,69,71],{"name":66,"role":32,"phone":67,"phoneExt":12,"email":68},"Grigori Kaplan, PhD","+61 9114 0412","grigori.kaplan@sydney.edu.au",{"name":70,"role":28,"phone":12,"phoneExt":12,"email":12},"Craig Phillips, PhD",{"name":72,"role":28,"phone":12,"phoneExt":12,"email":12},"Brendon Yee, PhD FRACP",{"type":74,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100465006","cpap-and-glucose-metabolism-in-non-diabetic-osa-subjects-100465006",false,"NCT05335083","CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects","The Impact of CPAP on Glucose Metabolism in Moderate-Severe Obstructive Sleep Apnoea Patients Without Diabetes - An Observational Study","Inclusion Criteria:\n\n1. Community dwelling adult males and females aged 18-65 years\n2. Polysomnography confirmed moderate to severe OSA with apnea hypopnea index (AHI) ≥15\u002Fhr within the past 60 months\n3. Able to give written informed consent\n4. Proficient in English\n\n6\\. Diagnosed non-diabetic as defined by the American Diabetes Association as any of the following recent (\\\u003C3 months) findings:\n\n1. Fasting glucose with a BGL \\\u003C7.0 mmol\u002FL\n2. Glucose tolerance with a 2-hour BGL of \\\u003C 11.1 mmol\u002FL after a formal 75g Oral Glucose Tolerance Test (OGTT)\n3. HbA1C of ≤ 6.5% 7. Possession or regular access to a mobile telephone with capability to download and run the Withings Sleep Anlayser App.\n\nExclusion Criteria:\n\n1. Clinically significant co-morbidity (e.g. myocardial infarction, congestive heart failure, stroke, arrythmia, chronic kidney or liver disease, epilepsy, head injury)\n2. Severe mental health disorders (e.g. current major depressive disorder, schizophrenia, bipolar disorder) that in the opinion of the investigator is not adequately treated or will significantly affect their participation in the study.\n3. Regular (\\>2 times per month) use of sleep-affecting medication (e.g. benzodiazepines, opioids, antidepressants)\n4. Regular night shift work or travel overseas within the last 2 weeks\n5. Sleep physician has advised against CPAP withdrawal\n6. Pregnancy\n7. Active smoking or routine alcohol use (more than 2 standard drinks a day) or excessive caffeine intake (\\>300 mg a day) or recent (in the past month) use of illicit drugs\n8. Current or previous diagnosis of diabetes mellitus (previous gestational diabetes mellitus not excluded)\n9. Current or recent (\\\u003C3 months) use of hypoglycaemic agents\n10. Undergoing a weight loss programme\n11. Contraindications for use of the FreeStyle Libre Pro Sensor. E.g. Known hypersensitivity to skin adhesives such as those used to attach the sensor to the arm.",true,"ALL","18 Years","65 Years",{"count":87,"type":88},100,"ESTIMATED","INTERVENTIONAL",[91],"NA","The purpose of the current study is to investigate whether alleviation of OSA by CPAP positively impacts glucose metabolism in non-diabetic patients.",[94,95],"Obstructive Sleep Apnea","Pre-diabetes","NOT_YET_RECRUITING","2025-03-25",{"date":99,"type":100},"2025-04-01","ACTUAL",{"date":102,"type":88},"2025-07-01",{"date":104,"type":88},"2027-02-28",{"name":5,"class":6},2]